Biology: Risk factor modification by OCs and HRT lipids and lipoproteins

Maturitas

Volumn 47, Issue 4, 2004, Pages 299-303

  Godsland, Ian F ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Hormone replacement therapies; Lipid metabolism; Oral contraceptive; Risk factor

Indexed keywords

CHYLOMICRON; CYPROTERONE ACETATE; DESOGESTREL; DESOGESTREL PLUS ETHINYLESTRADIOL; DYDROGESTERONE; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; GESTAGEN; HIGH DENSITY LIPOPROTEIN; LEVONORGESTREL; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; PROGESTERONE; SEX HORMONE; TIBOLONE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

CLINICAL TRIAL; CONFERENCE PAPER; DOWN REGULATION; DRUG EFFECT; DRUG FORMULATION; DRUG RESPONSE; ENDOTHELIUM LESION; HORMONAL CONTRACEPTION; HORMONE SUBSTITUTION; HUMAN; META ANALYSIS; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; ORAL CONTRACEPTION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN STRUCTURE; RISK FACTOR; RISK MANAGEMENT; SIDE EFFECT;

CHOLESTEROL, HDL; CHOLESTEROL, LDL; CONTRACEPTIVES, ORAL, COMBINED; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; LIPIDS; RISK FACTORS; TRIGLYCERIDES;

EID: 1942504093     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2003.10.013     Document Type: Conference Paper

References (30)

1. Barr D., Russ E., Eder H. Influence of estrogens on lipoproteins in atherosclerosis. Trans. Assoc. Am. Phys. 65:1952;102-111.
2. Godsland I.F., Winkler U., Lidegaard Ø., Crook D. The occlusive vascular diseases in oral contraceptive users: epidemiology, pathology and mechanisms. Drugs. 60:2000;721-869.
3. Packard C.J., Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Aretrioscler. Thromb. Vasc. Biol. 17:1997;3542-3556.
4. Hamilton C.A. Low-density lipoprotein and oxidised low-density lipoprotein: their role in the development of atherosclerosis. Pharmacol. Ther. 74:1997;55-72.
5. Austin M.A. Triglyceride, small, dense low-density lipoprotein, and the atherogenic lipoprotein phenotype. Curr. Atheroscler. Rep. 2:2000;200-207.
6. Havel R.J. Remnant lipoproteins as therapeutic targets. Curr. Opin. Lipidol. 11:2000;615-620.
7. Scanu A.M. The role of lipoprotein (a) in the pathogenesis of atherosclerotic cardiovascular disease and its utility as a predictor of coronary heart disease events. Curr. Cardiol. Rep. 3:2001;385-390.
8. Nofer J.R., Kehrel B., Fobker M., Levkau B., Assman G., von Eckardstein A. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis. 161:2002;1-16.
9. von Eckardstein A., Assman G. Prevention of coronary heart disease by raising HDL cholesterol. Curr. Opin. Lipidol. 11:2000;627-637.
10. Walsh B.W., Schiff I., Rosner B., Greenberg L., Ravnikar V., Sacks F.M. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N. Engl. J. Med. 325:1991;1196-1204.
11. Campos H., Sacks F.M., Walsh B.W., Schiff I., O'Hanesian M.A., Krauss R.M. Differential effects of estrogen on low-density lipoprotein subclasses in healthy postmenopausal women. Metabolism. 42:1993;1153-1158.
12. Ritsch A., Kaser S., Volgger B., Abfalter E., Sturm W., Ganzer H.et al. Enhancement of cholesteryl transfer in plasma by hormone-replacement therapy. Metabolism. 51:2002;599-604.
13. Homma H., Kurachi H., Nishio Y., Takeda T., Yamamoto T., Adachi K. Estrogen suppresses transcription of lipoprotein lipase gene. Existence of a unique estrogen response element on the lipoprotein lipase promoter. J. Biol. Chem. 275:2000;11404-11411.
14. Westerveld H.T., Kock L.A.W., van Rijn J.M., Erkelens D.W., de Bruin T.W.A. 17β-Estradiol improves postprandial lipid metabolism in postmenopausal women. J. Clin. Endocrinol. Metab. 80:1995;249-253.
15. Sanada M., Nakagawa H., Kodama I., Sakasita T., Ohama K. Three-year study of estrogen alone versus combined with progestin in postmenopausal women with or without hypercholesterolemia. Metabolism. 49:2000;784-789.
16. Windler E., Kovanen P., Chao Y., Brown M., Havel R., Goldstein J. The estradiol-stimulated lipoprotein receptors of rat liver. A binding site that membrane mediates the uptake of rat lipoproteins containing apoproteins B and E. J. Biol. Chem. 255:1980;10464-10471.
17. Hoogerbrugge N., Zillikens M.C., Jansen H., Meeter K., Deckers J.W., Birkenhager J.C. Estrogen replacement decreases the level of antibodies against oxidized low-density lipoprotein in postmenopausal women with coronary heart disease. Metabolism. 47:1998;675-680.
18. Su W., Campos H., Judge H., Walsh B., Sacks F. Metabolism of apo(a) and apoB100 of lipoprotein (a) in women: effect of postmenopausal estrogen replacement. J. Clin. Endocrinol. Metab. 83:1998;3267-3276.
19. Schaefer E., Foster D., Zech L., Lindgren F., Brewer H. Jr., Levy R. The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females. J. Clin. Endocrinol. Metab. 57:1983;262-267.
20. Brinton E.A. Oral estrogen replacement therapy in postmenopausal women selectively raises levels and production rates of lipoprotein A-I and lowers hepatic lipase activity without lowering the fractional catabolic rate. Arterioscler. Thromb. Vasc. Biol. 16:1996;431-440.
21. Jones D.R., Schmidt R.J., Pickard R.T., Foxworthy P.S., Eacho P.I. Estrogen receptor-mediated repression of human hepatic lipase gene transcription. J. Lipid Res. 43:2002;383-391.
22. Fluiter K., van der Westhuijzen D.R., van Berkel T.J. In vivo regulation of scavenger receptor B1 and the selective uptake of high density lipoprotein cholesteryl esters in rat liver parenchymal and Kupffer cells. J. Biol. Chem. 273:1998;8434-8438.
23. Godsland I.F. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein and apolipoprotein (a) concentrations: summary analysis of studies published between 1974 and 2000. Fertil. Steril. 75:2001;898-915.
24. Samsioe G. Comparative effects of the oral contraceptive combinations 0.150. mg desogestrel + 0.030 mg ethinyloestradiol and 0.150 mg levonorgestrel + 0.030 mg ethinyloestradiol on lipid and lipoprotein metabolism in healthy female volunteers Contraception. 25:1982;487-503.
25. Godsland I., Crook D., Simpson R., Proudler T., Felton C., Lees B.et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N. Engl. J. Med. 323:1990;1375-1381.
26. van Rooijen M., von Schoultz B., Silveira A., Hamsten A., Bremme K. Different effects of oral contraceptives containing levonorgestrel or desogestrel on plasma lipoproteins and coagulation factor VII. Am. J. Obstet. Gynecol. 186:2002;44-48.
27. Marsh M.S., Crook D., Whitcroft S.I., Worthington M., Whitehead M.I., Stevenson J.C. Effect of continuous combined estrogen and desogestrel hormone replacement therapy on serum lipids and lipoproteins. Obstet. Gynecol. 83:1994;19-23.
28. von Eckardstein A., Schmiddem K., Hövels A., Gülbhaçe E., Schüller-Lüttman S., Elbers J.et al. Lowering of HDL cholesterol in post-menopausal women by tibolone is not associated with changes in cholesterol efflux capacity or paraoxonase activity. Atherosclerosis. 159:2001;433-439.
29. Mikkola T.S., Anthony M.S., Clarkson T.B., St Clair R.W. Serum cholesterol efflux potential in postmenopausal monkeys treated with tibolone or conjugated estrogens. Metabolism. 51:2002;523-530.
30. WHI Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-33.